Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Hong Kong
  4. Hong Kong Stock Exchange
  5. Ocumension Therapeutics
  6. Company
    1477   KYG674111011

OCUMENSION THERAPEUTICS

(1477)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Ocumension Therapeutics is a China-based holding company principally involved in the discovering, developing and commercializing ophthalmic therapies. Its main products include OT-401 (YUTIQ), OT-1001 (ZERVIATE), OT-502 (DEXYCU), OT-301 (NCX 470), OT-101 and OT-202, among others. The Company conducts its businesses in the domestic market.

Number of employees : 136 people.
Sales per Business
20192020Delta
Ophthalmic Pharmaceutical Platform0.22100%14.72100% +6730.5%
HKD in Million
Sales per region
20192020Delta
China0.22100%14.72100% +6730.5%
HKD in Million
Managers
Name Title Age Since
Ye Liu Chief Executive Officer & Executive Director 50 2018
Jian Ping Yang Finance Director - -
Chang Dong Liu, Dr. Chief Scientific Officer 59 2019
Dong Hong Chen, Dr. Chief Medical Officer 50 2019
Jie Ting Jiang Director-Human Resources & Administration - -
Ting Yuk Wu Independent Non-Executive Director 66 2020
Lian Ming He Independent Non-Executive Director 56 -
Yi Ran Huang Independent Non-Executive Director 66 -
Yun Ji Secretary & Director-Strategic Project - 2020
Pui Chun Suen Secretary 42 2020
Members of the board
Name Title Age Since
Lian Yong Chen, Dr. Executive Chairman 58 2020
Ye Liu Chief Executive Officer & Executive Director 50 2018
Shen Ye Director - -
Qin Xie Member-Supervisory Board - -
Zhao Peng Hu, Dr. Executive Director & VP-Regulatory Affairs 48 2020
Wei Li, Dr. Executive Director 49 2020
Yan Ling Cao Non-Executive Director 37 2019
Ting Yuk Wu Independent Non-Executive Director 66 2020
Lian Ming He Independent Non-Executive Director 56 -
Yi Ran Huang Independent Non-Executive Director 66 -
Shareholders
NameEquities%
6 Dimensions Capital 126,200,000 18.9%
Suzhou Yunchang Investment Consulting Co. Ltd. 126,200,000 18.9%
Boyu Capital Advisory Co. Ltd. 78,214,230 11.7%
Temasek Holdings Pte Ltd. (Investment Management) 59,446,400 8.92%
Capital Research & Management Co. (World Investors) 47,963,490 7.19%
FIL Investment Management (Hong Kong) Ltd. 21,229,644 3.18%
Ye Liu 14,329,730 2.15%
Capital Research & Management Co. (Global Investors) 9,650,966 1.45%
The Vanguard Group, Inc. 5,938,500 0.89%
UBS Asset Management (Hong Kong) Ltd. 4,227,000 0.63%
Holdings
NameEquities%Valuation
EYEPOINT PHARMACEUTICALS, INC. (EYPT) 3,010,722 8.88% 36,851,237 USD
ALIMERA SCIENCES, INC. (ALIM) 1,144,945 16.5% 5,873,568 USD
Brand Portfolio
In partnership withAllbrands.markets
More brands of Ocumension Therapeutics
Sector Other Pharmaceuticals
1st jan.Capi. (M$)
OCUMENSION THERAPEUTICS-31.43%1 084
JOHNSON & JOHNSON-1.57%443 277
ROCHE HOLDING AG-7.91%306 143
PFIZER, INC.-10.23%297 538
ABBVIE INC.-0.86%237 303
ELI LILLY AND COMPANY-13.89%215 642
NOVO NORDISK A/S-15.89%213 450
MERCK & CO., INC.3.26%199 903
NOVARTIS AG-2.64%189 740
ASTRAZENECA PLC-2.27%177 586
BRISTOL-MYERS SQUIBB COMPANY-0.18%138 151
SANOFI3.79%130 219
AMGEN INC.-1.08%125 349
GLAXOSMITHKLINE PLC1.57%110 966
BAYER AG9.68%57 141
CHUGAI PHARMACEUTICAL CO., LTD-1.02%53 161
TAKEDA PHARMACEUTICAL COMPANY LIMITED5.45%45 060
DAIICHI SANKYO CO., LTD.-11.11%43 582
JIANGSU HENGRUI MEDICINE CO., LTD.-18.97%42 423
ASTELLAS PHARMA INC.0.72%30 528
HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY-18.88%19 826